Platform Production Technology

The BRS “Intelligent Molecules” Expression System employs a proprietary manufacturing process that allows the production of a wide variety of soluble and properly folded proteins and signaling molecules from multiple stem cell types important to immune modulation, and tissue repair and regeneration. The advantages of the process are in the production of biologically active proteins, exosomes, and signaling molecules, developing a “systems therapeutic” yielding a combination of many molecules, that act at multiple targets, resulting in a synergistic therapeutic with emergent therapeutic value.

Furthermore, the production of the SRM (stem cell released molecules) does not require downstream solubilization, refolding, or other processes. Additionally, the process offers reduced purification requirements and lower production costs than other pharmacological and biological processes. The production of a therapeutic with a multitude of molecules represents a multi-targeted, systems biology approach to designing and manufacturing therapeutics.

In the BRS “Intelligent Molecules” Expression System, multiple stem cell types are used to express SRM and thus the term “S²RM®” is used to denote that two or more types of stem cells are used to produce a synergistic effect. The combination of stem cells used to develop each therapeutic depend on the condition being treated, and the type of tissue underlying the condition. Included in the S²RM® is the BRS Exosome Delivery System that drives the active molecules through the layers of tissue into the target site, effectuating regeneration and repair in all damaged tissue regardless of the depth or remotness of the target.

Unlike other so-called stem cell therapeutics, such as iPSCs and parthenogenetic stem cells, which are artificially induced “stem cells,” and suffer from genetic and epigenetic programming errors, the adult stem cells in S²RM® Technology are genetically and epigenetically normal. Further, the production of some “stem cell” therapeutics does not allow the molecules to be completely processed in the cell and allow for proper post-translational modifications.

That is, the S²RM® Technology allows the stem cells to fully process the molecules to the point of exosome production and release, including complete post-translational modification with resultant normal molecular folding characteristics and moiety construction. Thus, unlike iPSCs and parthenogenetic “stem cells” that don’t produce the complete set of the natural molecules of a stem cell and also fail to complete the full assembly of each of the molecules, the true adult stem cells in S²RM® Technology display correct genetic and epigenetic coding, with complete post-translational modifications to produce a natural and full complement of molecules with complete post-translational modifications and hence full efficacy and a natural safety profile.